The NCCN Guidelines now recommend the use of fluoroestradiol PET imaging for systemic staging in patients with invasive lobular breast cancer, following an update from GE HealthCare regarding its imaging agent, Cerianna (fluoroestradiol F18). This recommendation aims to enhance diagnostic accuracy and early intervention for recurrent or metastatic lobular breast cancer, which is often difficult to detect. Cerianna is the only FDA-approved imaging agent for assessing estrogen receptor positive lesions, making it a valuable tool in a clinical setting. The guidelines, established by an expert working group, emphasize the importance of PET imaging in diagnosing this hard-to-detect cancer type, potentially improving insurance coverage and aligned clinical decisions.
Fri, 30 May 2025 21:23:56 GMT | Imaging Technology News